Cholecystokinin coexists with dopamine in mesolimbic neurons in mammalian brain. When injected directly into the nucleus accumbens, cholecystokinin (CCK) potentiated dopamine (DA)-induced hyperlocomotion and apomorphine-induced stereotypy. These effects were not mimicked by nonsulfated CCK, but were blocked by proglumide, a putative CCK antagonist, as well as by antisera raised against sulfated CCK. CCK alone had no effect on locomotion or stereotypy, indicating that this peptide acts primarily as a modulator of DA-mediated behaviors in the mesolimbic pathway. In addition, CCK did not potentiate DA-induced hyperlocomotion or apomorphine-induced stereotypy when injected into the caudate nucleus, where CCK and DA are localized in separate neurons in rats. Facilitation of DA-mediated behaviors by CCK may represent a functional interaction specific to the neuromodulator-neurotransmitter coexistence phenomenon.
Abstract
Cholecystokinin coexists with dopamine in mesolimbic neurons in mammalian brain. When injected directly into the nucleus accumbens, cholecystokinin (CCK) potentiated dopamine (DA)-induced hyperlocomotion and apomorphine-induced stereotypy. These effects were not mimicked by nonsulfated CCK, but were blocked by proglumide, a putative CCK antagonist, as well as by antisera raised against sulfated CCK. CCK alone had no effect on locomotion or stereotypy, indicating that this peptide acts primarily as a modulator of DA-mediated behaviors in the mesolimbic pathway. In addition, CCK did not potentiate DA-induced hyperlocomotion or apomorphine-induced stereotypy when injected into the caudate nucleus, where CCK and DA are localized in separate neurons in rats. Facilitation of DA-mediated behaviors by CCK may represent a functional interaction specific to the neuromodulator-neurotransmitter coexistence phenomenon.
Several recent immunocytochemical studies suggest that cholecystokinin (CCK) is co-localized in the same neurons as dopamine (DA) In the mesolimbic pathway of the rat. lmmunofluorescence micrographs from ventral tegmental sections incubated with antisera to gastrin/CCK and subsequently to tyrosine hydroxylase showed identity between CCK-immunoreactive neurons and DA-immunoreactive neurons (Hokfelt et al., 1980a) . Combined immunocytochemistry and retrograde tracing of fluorescent dyes showed CCK/ DA-containing cell bodies in the ventral tegmental area projecting to the caudal, medial nucleus accumbens (Hbkfelt et al., 1980b) , amygdala, and olfactory tubercles (Fallon et al., 1983 ). Injection of 6-hydroxydopamine into the ventral mesencephalon produced a parallel reduction in both tyrosine hydroxylase immunoreactivity and gastrin/CCK immunoreactivity (Hokfelt et al., 1980b; Studler et al., 1981; Marley et al., 1982) .
Functional studies indicate interactions between CCK and DA in vitro and in viva. DA potentiated veratridine-induced release of CCK (Meyer and Krauss, 1983) whereas CCK inhibited release of DA from cat caudate nucleus (Markstein and Hdkfelt, 1984) and rat nucleus accumbens (Voight and Wang, 1984) while stimulating release of DA from rat striatum (Chesselet, 1984) and mouse striatum (Kovacs et al., 1981) . In addition, CCK reduced DA turnover in the nucleus accumbens and caudate nucleus of the rat (Fuxe et al., 1980) . CCK levels in the striatum and mesolimbic system increased after chronic DA receptor blockade (Frey, 1983) . DA-binding sites in the cerebral cortex and olfactory tubercles showed an increase in number and a decrease in affinity after CCK treatment (Murphy and Schuster, 1982; Agnati et al., 1983) .
Neurophysiological studies of extracellular recording from the ventral tegmental neurons and the nucleus accumbens found that CCK enhances the inhibition of neuronal firing induced by DA and apomorphine (APO), even though CCK is excitatory when administered alone (Hommer and Skirboll, 1983; Crawley et al., 1984; DeFrance et al., 1984) . Taken together, these several lines of evrdence support the concept that CCK coexists with DA in the mesolimbic system, functioning as a modulator of dopaminergic activity.
Although the behavioral actions of peripheral CCK on digestive processes and food intake have been elaborated (Mutt, 1978; Smith and Gibbs, 1981; Morley, 1982; Crawley et al., 1982 ) the behavioral functions of central CCK remain obscure. High doses of CCK, injected intraventricularly, decrease open field behaviors (Van Ree et al., 1983; Katsuura et al., 1984) suppress operant responding (Cohen et al., 1983) and induce sedation and catalepsy (Zetler, 1980 (Zetler, , 1982 . However, these effects may be of peripheral origin, since the microgram doses of CCK employed in these studies are likely to enter the systemic circulation (Passaro et al., 1982) . Intrathecal administration of the CCK antagonist, proglumide, potentiated opiate analgesia, suggesting that in the spinal cord CCK may modulate opiate function (Faris et al., 1983; Watkins et al., 1984) .
Since the mesolimbic DA pathway has been shown to have relatively specific behavioral actions on locomotion (Creese and Iversen, 1974; Iversen, 1977) and also plays a role in the induction of stereotypy (Costall and Naylor, 1975; Costal et al., 1977; Joyce, 1983) CCK might be expected to elicit the same set of motor behaviors when injected into the nucleus accumbens. Studies using high doses of CCK found no direct effect of CCK on stereotypy or locomotion (Schneider et al., 1983; Widerlov et al., 1983; Hamilton et al., 1984) . Microgram doses of CCK injected into the nucleus accumbens were found to inhibit amphetamine-induced hyperlocomotion (Schneider et al., 1983) and APO-induced stereotypy (Ellinwood et al., 1983) . However, physiologically relevant doses of CCK have not been tested in the nucleus accumbens for their behavioral effects.
The studies presented here were undertaken to provide a systematic behavioral analysis of a wide range of doses of CCK injected directly into the nucleus accumbens. The effects of CCK administered alone, of CCK administered in conjunction with DA, and of CCK administered in conjunction with APO were tested on both the hyperlocomotion paradigm and the stereotypy paradigm. In addition, since CCK in the substantia nigra and in the caudate nucleus 1972 appears to be localized in a population of neurons separate from those containing DA (Hiikfelt et al., 1980b; Marley et al., 1982; Gilles et al., 1983) , the effects of CCK alone and in conjunction with DA or APO on stereotypy and hyperlocomotion were also tested in the caudate nucleus. Terminals containing both CCK and DA, from ventral tegmental neurons in which CCK and DA co-extst, have been demonstrated in this region (Hbkfelt et al., 1980a, b a In all studies, animals were used four times, with intervals of at least 4 days between uses, In a Latin Square Design (Fisher, 1950) . See the text for details.
b SAL, saline.
of Pharmacology, University of St. Louis School of Medicine, St. Louis, MO), and 0.9% physlologlcal saline (Abbott Laboratories, Chicago, IL). In all studies, animals were used four times, with Intervals of at least 4 days between uses, In a Latin Square Design (Fisher, 1950) . For example, in experiments 2 and 4, animals were dtvided Into four treatment groups: saline, DA, CCK, and DA + CCK, for each dose of CCK (Table I) , On a given test day, locomotion scores for saline and DA were required to be not significantly different from scores obtatned for saline and DA on previous test days for lncluslon of the data on CCK and DA + CCK in the present study.
Two (IO, 20, 30, or 40 ng) or saline (0.2 ~1) was injected into each side of the nucleus accumbens, 1 min before scoring of ambulatory locomotion as described above. APO (0.1, 0.15, 0.2, 0.3, or 0.4 mg/kg) or saline (0.2 ml) was InJected subcutaneously 15 min before scoring of stereotypy as described above. These doses were chosen from previous studies (Pilnenburg and Van Rossum, 1973; Costall and Naylor, 1975; Iversen, 1977; Joyce, 1983) , to determine the optlmal doses of DA and apomorphine for elicitation of hyperlocomotion and stereotypy, respectively. Experiment 2 investigated the effects of CCK on ambulatory locomotor activity. CCK (2, 20, or 200 pg; 2, 20, or 200 ng) or saline, in 0.2 ~1, was bilaterally injected over a 1-mln period into the nucleus accumbens as described above. CCK (4, 40, or 400 pg; or 4, 40, or 400 ng) or saline, In 0.5 ~1, was bilaterally injected over a 1 -min period into the caudate nucleus. One minute after injection, rats were placed into the Digiscan activity monitor for 15 min, as described above. Experiment 3 investigated the effects of CCK on stereotyped behavior. CCK (2, 20, or 200 pg; 2, 20, or 200 ng; or 2 pg) or saline, In 0.2 ~1, was injected bilaterally over a l-mln period into the nucleus accumbens, as described above. CCK (4, 40, or 400 pg; or 4, 40, or 400 ng) or saline, in 0.5 ~1, was injected bilaterally over a 1 -min period Into the caudate nucleus, as described above. Stereotyped sniffing, gnawing, and licking were scored for 15 min, beginning 1 min after in]ection, as described above. Experiment 4 investigated the effects of CCK on DA-induced hyperlocomotion. CCK (2, 20, or 200 pg; 2, 20, or 200 ng; or 2 pg) or saline was combined wrth DA (20 fig/O.2 ~1) and injected bilaterally over a I-min period into the nucleus accumbens, as described above. CCK (4, 40, or 400 pg; or 4, 40, or 400 ng) or saline was combined with DA (20 pg/O.5 @I) and injected bilaterally over a 1 -mln period into the caudate nucleus, as described above. One minute after injection, rats were placed into the Diglscan activity monitor for 15 min, as described above. Results Figure 2A shows the dose-response curve for DA injected into the nucleus accumbens on locomotor activity. ANOVA yielded a significant effect of dose: f4,20 = 9.83, p < 0.01. Newman-Keuls a posteriori analysis for significance of individual means showed a significant increase in locomotion after doses 20, 30, and 40 pg of DA injected bilaterally into each nucleus accumbens ( l *p < O.Oi), as compared to saline controls (N = 5 for each dose); data are represented as mean + SEM. A dose of 20 pg/side was chosen, to employ a dose of DA which significantly increased locomotion without approaching a maximal response. Figure 26 shows the dose-response curve for apomorphine injected subcutaneously on stereotyped sniffing behaviors. ANOVA yielded a significant effect of dose: F5, 25 = 11.45, p < 0.01. Newman-Keuls analysis showed a significant increase in stereotypy score after doses of 0.10, 0.15, 0.2, 0.3, and 0.4 mg/kg of APO subcutaneously, as compared to saline controls (*p < 0.05; **p < 0.01; N = 5 for each dose; data represented as mean + SEM). A dose of 0.2 mg/kg, s.c., was chosen as approximately half-maximal from this curve, to employ a dose of APO which significantly increased stereotypy without approaching a maximal response. Figure 3A shows the lack of effects of CCK on locomotor activity when injected Into the nucleus accumbens over the dose range of 2 pg to 200 rig/side, as compared to saline-injected controls (AN-OVA: F5, 25 =1.41, not significant; N = 5 for each dose). Figure 38 shows the lack of effect of CCK on locomotor activity when injected into the caudate nucleus over the dose range of 4 pg to 400 ng/ side, as compared to saline-injected controls (ANOVA: &, = 1.54, not significant; N = 5 for each dose). Figure 4A shows the lack of effect of CCK on stereotypy scores when injected into the nucleus accumbens over the dose range of 2 pg to 2 pg/side, as compared to saline-injected controls (ANOVA: F6, 28 = 2.25, not significant; N = 5 for each dose). Figure 48 shows the lack of effect of CCK on stereotypy when injected into the caudate nucleus over the dose range of 4 pg to 400 rig/side, as compared to saline-injected controls (ANOVA: F5,23 = 2.61, not significant; N = 5 for each dose). Figure 5A shows a significant effect of CCK on DA-induced hyperlocomotion when CCK was injected in combination with DA into the nucleus accumbens. CCK significantly increased the locomotion scores at doses from 20 pg to 200 rig/side when administered with DA (20 wg/side), as compared to DA (20 pg/side) + saline (ANOVA: F+,8 = 4.46, p < 0.01; Newman-Keuls *p < 0.05, **p < 0.01; N = 8 for each dose). Figure 5B shows that CCK had no effect on locomotion when injected in combinatton with DA tnto the caudate nucleus in CCK doses of from 4 pg/side to 400 ng/ side + DA (20 Fg/side), as compared to DA (20 pg/side) + saline (ANOVA: I& = 1.54, not significant; N = 8 for each dose). Figure 6A shows a significant effect of CCK on APO-induced stereotypy when CCK was injected into the nucleus accumbens 15 min after subcutaneous injection of APO. CCK significantly increased Figure 3 . A, CCK had no effect on locomotor actlvlty when injected into the nucleus accumbens over the dose range of 2 pg to 200 rig/nucleus accumbens, as compared to saline-Injected controls. B, CCK had no effect on locomotor activity when injected into the caudate nucleus over the dose range of 4 pg to 400 ng/caudate nucleus, as compared to sallneqected controls. N = 5 for each dose of each treatment.
the stereotypy scores at doses from 20 pg to 200 rig/side when administered after APO (0.2 mg/kg, s.c.), as compared to APO (0.2 mg/kg, s.c.) + saline (ANOVA: Fs,~~ = 7.64, p < 0.01; NewmanKeuls *p < 0.05, **p < 0.01; N = 8 for each dose). Figure 613 shows that CCK had no effect on stereotypy when injected into the caudate nucleus 15 min after subcutaneous injection of APO. Doses of CCK from 40 pg to 400 rig/side following APO (0.2 mg/kg, s.c.) were not significantly different from APO (0.2 mg/kg, s.c.) + saline (ANOVA: I&, = 1.93, not significant; N = 8 for each dose). Figure 7 shows the lack of effect of unsulfated CCK8 on DAinduced hyperlocomotion and APO-induced stereotypy in the nucleus accumbens. Illustrated are the significant effects of CCKsulfated (2 rig/side) on DA-induced hyperlocomotion and APOinduced stereotypy, using grouped t test statistics to compare DA + CCK to DA + saline, and APO + CCK to APO + saline (*p < 0.05). CCK-nonsulfated did not produce an effect on DA-induced hyperlocomotion or APO-induced stereotypy when injected into the nucleus accumbens In a dose of 2 rig/side, as compared to DA + saline or to APO + saline by grouped t test statistics. Since the affinity of CCK-nonsulfated is approximately 1000.fold less than CCK-sulfated for the pancreatic CCK receptor (Gardner et al, 1977; lnnis and Snyder, 1980) , and since controversy exists on the relative affinities of CCK-nonsulfated and CCK-sulfated for the brain CCK receptor (Hays et al., 1980, lnnis and Snyder, 1980; Saito et al., 1980; Praissman et al., 1983; Van Dijk, et al., 1984) , a dose of CCKnonsulfated which was 1000.fold higher than the active dose of CCK-sulfated was also tested. CCK-nonsulfated did not produce an effect on DA-induced hyperlocomotion or APO-induced stereotypy when injected into the nucleus accumbens in a dose of 2 pg/side, as compared to DA + saline or APO + saline by grouped t test statistics. As found in experiments 4 and 5, presented in Figures 5A and 6A, CCK-sulfated had no effect on DA-induced hyperlocomotion or APO-Induced stereotypy when injected into the nucleus accumbens in a dose of 2 pg/side, as compared to DA + saline or APO + saline by grouped t test statistics (N = 6 for each dose of treatment, p < 0.05). Figure 8A shows the ability of the relatively specific CCK receptor antagonist, proglumide, to block the effects of CCK on DA-induced hyperlocomotlon.
Proglumide (8 or 20 pg/slde) + saline had no effect on base line locomotion (ANOVA: F2, 15 = 1.33, not significant), as compared to saline + saline. Proglumide Figure 88 shows the ability of rabbit antiserum raised against CCK-8-sulfated to block the effects of CCK on DAinduced hyperlocomotion. Undiluted preimmune serum, undiluted CCK antiserum, and CCK antiserum diluted I:5 had no effect on base line locomotion (ANOVA: F 3,20 = 0.98, not significant), as compared to saline + saline. Undiluted preimmune serum, undiluted CCK antiserum, and I:5 diluted CCK antiserum had no significant effect on DA-induced hyperlocomotion (F3,20 = 2.36, not significant), as compared to saline + DA (20 Kg/side). CCK antiserum, undiluted and diluted 15, significantly inhibited the CCK-induced increase in DA-induced hyperlocomotion (F3,20 = 7.24, p < 0.01; NewmanKeuls "p < 0.05), as compared to saline + DA (20 pg/side) + CCK (200 pg/side). Preimmune serum had no effect on the CCK-induced increase in DA-induced hyperlocomotion (N = 6 for each dose of each treatment). behavioral effects of systemically administered APO on stereotypy of elicitation of stereotypy may involve a feedback pathway from the when Injected into the nucleus accumbens of awake rats. Effective caudate nucleus to the nucleus accumbens (Costall et al., 1977) . doses of CCK ranged from 20 pg to 200 ng, which are within the The use of stereotypy tests in the present paradigm for both the range of concentrations that have been reported for endogenous caudate nucleus and the nucleus accumbens was based on these CCK in the nucleus accumbens (Belnfeld and Palkovits, 1981) . The recent findings. The ability of CCK injected into the nucleus accumfacllttatory effects of CCK appear to occur at physiologically relevant bens to potentiate APO-induced stereotypy lends further support to concentrations. a role for the nucleus accumbens in stereotyped behaviors. CCK did not show any effects on locomotion or stereotypy when
The lack of effect of CCK alone in the caudate nucleus, and in administered alone Into the nucleus accumbens, over a wide dose combination with systemic APO, provides evidence that CCK does range. CCK, therefore, does not appear to have any direct postsynnot potentlate behaviors mediated by a dopaminergic agonist in the aptic activity in the nucleus accumbens which would be equivalent caudate nucleus. However, the inability of the combination of CCK or analagous to the postsynaptic actions of DA on the behaviors + DA to induce hyperlocomotion when injected into the caudate tested. This finding leads to the suggestion that CCK may act nucleus cannot be considered definitive, since DA at 20 pg/side did primarily as a modulator of DA in the nucleus accumbens.
not produce hyperlocomotion in the caudate nucleus. Hyperlocom-CCK had no effect on stereotypy when administered alone into otion is thought to be mediated primarily in the mesolimbic projection the caudate nucleus, or in conjunction with intracerebral DA or to the nucleus accumbens rather than the caudate nucleus (Pijnensystemic APO. Stereotyped snuffing has been considered as primarily burg and van Rossum, 1973; Costall and Naylor, 1975 ; Costall et a nlgrostrlatal behavior (Creese and Iversen, 1974; Iversen, 1977; al., 1977; Iversen, 1977) . A pilot dose-response study of DA injected Joyce, 1983). More recent evidence suggests that stereotypy can into the caudate nucleus did not show any doses of DA which also be elicited from the nucleus accumbens (Costall and Naylor injected into the caudate nucleus. The main finding at present, however, indicates that CCK does not increase or decrease stereotyped behaviors most closely linked to the caudate nucleus. If further studies confirm the ability of CCK to potentiate behavioral effects of DA and dopaminergic agonists in the nucleus accumbens, but not in the caudate nucleus, the present paradigm could be used to test other anatomical regions receiving terminals from the CCK/ DA-containing neurons in the ventral tegmentum, such as the olfactory tubercles, the prefrontal cortex, and the amygdala. Unsulfated CCK had no effect on DA-induced hyperlocomotion or APO-induced stereotypy in the nucleus accumbens. This lack of effect does not appear to be a function of a potency differential, since a dose three orders of magnitude above effective sulfated CCK doses was also without effect. Receptor-binding studies of CCK in the brain report no difference, or only one order of magnitude difference, between sulfated and unsulfated forms of CCK (Hays et al., 1980; lnnis and Snyder, 1980; Van Dijk et al., 1984) . Behavioral studies have reported either no difference or small differences in effects of sulfated and unsulfated CCK (Itoh and Katsuura, 1981; Jurna and Zetler, 1981; Kovacs et al., 1981) . The present study provides evidence for a modulatory function of CCK on dopaminergic activity which is specific for the sulfated form of the octapeptide.
Two pharmacological antagonists of CCK blocked the facilitatory effect of CCK on dopaminergic actions, indicating some degree of pharmacological specificity for the CCK effect. Proglumide is a glutaramic acid derivative developed as a specific antagonist of CCK at receptors in the pancreas and gall bladder. Proglumide was shown to block the physiological effects of CCK in stimulating release of pancreatic amylase (Gardner et al., 1977; Hahne et al., 1981) . Proglumide has also been shown to block behavioral effects of peripherally and centrally administered CCK (Collins et al., 1983; Hoebel and Aulisi, 1984; Schneider et al., 1985) and electrophysiological effects of centrally administered CCK (Chiodo and Bunney, 1983) . In the present paradigm, proglumide blocked the ability of CCK to enhance DA-induced hyperlocomotion when injected directly into the nucleus accumbens. The effective dose for this action of proglumide was 20 pg, as compared to the minimum effective dose of CCK, 20 pg. Proglumide does not appear to be a potent antagonist of CCK in this paradigm. However, it may be pharmacologically specific, since proglumide injected alone, or in combination with DA, had no effect on either spontaneous locomotion or on DA-induced hyperlocomotion. Antiserum raised against sulfated CCK8 provides an immunologically determined, pharmacologically specific antagonist of CCK. Undiluted antiserum and 15 diluted antiserum effectively blocked the actions of CCK on DA-induced hyperlocomotion. Preimmune serum, tested as a control for nonspecific effects of serum injected into the nucleus accumbens, had no effect on the actions of CCK. As with proglumide, CCK antibodies had no effect on spontaneous locomotion and did not effect DA-induced hyperlocomotion, indicating pharmacologic specificity to the facilatatory effects of CCK. The at this dose (*, p < 0 05 by grouped t test statlstlcs). Unsulfated CCK at 2 pg/slde, a dose 1000.fold higher than the active dose of sulfated CCK, also had no effect on DA-Induced hyperlocomotlon or APO-Induced stereotypy. N = 6 for each dose of each treatment. Prermmune undi l uted serum had no effect on the CCK-Induced Increase i n DA-Induced hyperlocomotion. Prermmune serum and antiserum had no effect on DA-i nduced hyperlocomotron or on base l i ne locomotron. Vol. 5, No. 8, Aug. 1985 To determine definitively the functional specificity of CCK in potentiating dopamine-induced behaviors in the nucleus accumbens, other peptides can be tested in the present paradigm. Several studies have addressed the question of peptides interacting with DA in the nucleus accumbens. Nemeroff et al. (1983) demonstrated that neurotensin microinjected into the nucleus accumbens antagonizes DA-induced increases in locomotion and rearing. Kalivas et al. (1984) have demonstrated that methionine-enkephalin increases locomotor activity when injected into the nucleus accumbens, either alone or in combination with DA. Since the nucleus accumbens contains a large number of neuropeptides, it is not surprising that other peptides influence dopaminergic functions. CCK appears to be the first peptide demonstrated to increase the response to dopaminergic functions, without having an effect alone. However, the functional specificity of this CCK-DA interaction must be further explored with a variety of neuropeptides.
In conclusion, CCK microinfused into the nucleus accumbens potentiated DA-induced hyperlocomotion and APO-induced stereotypy. The potentiation was blocked by the CCK receptor antagonist, proglumide, and by rabbit antiserum raised against CCK. Unsulfated CCK was ineffective in this paradigm. CCK had no effect alone on locomotion or stereotypy, suggesting that, behaviorally, CCK acts as a modulator of dopaminergic function. The mechanism of action for the observed modulation is unknown. Possibilities include postsynaptrc receptors in the nucleus accumbens, where a CCK-binding site could be linked to a DA receptor, or an interaction between CCK and DA at a presynaptic uptake or release site in the nucleus accumbens. CCK microinfused into the caudate nucleus did not affect APO-induced stereotypy and did not have any effect alone on stereotypy or locomotion. Since CCK and DA are known to coexist in the mesolimbic pathway from the ventral tegmental neurons to the nucleus accumbens, but are located in separate neurons in the substantia nigra and in the caudate nucleus (Hbkfelt et al., 1980a, b) , the CCK-DA behavioral facilitation phenomenon may represent a mechanism specific to a site of coexistence.
